- Home
- SPRC vs PCSA Comparison
SPRC vs PCSA Comparison
Compare SPRC & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRC
- PCSA
- Stock Information
- Founded
- SPRC 2004
- PCSA 2011
- Country
- SPRC Israel
- PCSA United States
- Employees
- SPRC N/A
- PCSA N/A
- Industry
- SPRC Biotechnology: Pharmaceutical Preparations
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- SPRC Health Care
- PCSA Health Care
- Exchange
- SPRC Nasdaq
- PCSA Nasdaq
- Market Cap
- SPRC 3.4M
- PCSA 3.3M
- IPO Year
- SPRC N/A
- PCSA N/A
- Fundamental
- Price
- SPRC $0.30
- PCSA $0.21
- Analyst Decision
- SPRC
- PCSA Strong Buy
- Analyst Count
- SPRC 0
- PCSA 1
- Target Price
- SPRC N/A
- PCSA $2.00
- AVG Volume (30 Days)
- SPRC 195.0K
- PCSA 46.5M
- Earning Date
- SPRC 02-15-2025
- PCSA 08-12-2025
- Dividend Yield
- SPRC N/A
- PCSA N/A
- EPS Growth
- SPRC N/A
- PCSA N/A
- EPS
- SPRC N/A
- PCSA N/A
- Revenue
- SPRC $1,306,000.00
- PCSA N/A
- Revenue This Year
- SPRC N/A
- PCSA N/A
- Revenue Next Year
- SPRC N/A
- PCSA N/A
- P/E Ratio
- SPRC N/A
- PCSA N/A
- Revenue Growth
- SPRC N/A
- PCSA N/A
- 52 Week Low
- SPRC $0.20
- PCSA $0.15
- 52 Week High
- SPRC $1.79
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- SPRC 49.11
- PCSA 41.15
- Support Level
- SPRC $0.29
- PCSA $0.19
- Resistance Level
- SPRC $0.34
- PCSA $0.33
- Average True Range (ATR)
- SPRC 0.02
- PCSA 0.09
- MACD
- SPRC -0.00
- PCSA -0.01
- Stochastic Oscillator
- SPRC 33.33
- PCSA 2.52
About SPRC SciSparc Ltd.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).